Literature DB >> 21976377

Accuracy and cost comparison in medical testing using sequential testing strategies.

Anwar E Ahmed1, Donna K McClish, Christine M Schubert.   

Abstract

The practice of sequential testing is followed by the evaluation of accuracy, but not by the evaluation of cost. This paper focuses on three logic rules for combining two sequences of tests: believe the positive (BP), which diagnoses disease if any of two tests is positive, believe the negative (BN), which diagnoses disease if any of two tests is negative, and believe the extreme (BE), which diagnoses disease if the first test is positive or, after a first inconclusive test, a second test is positive for disease. Comparisons of these strategies are provided in terms of accuracy using false positive rate, sensitivity pairs that make up the maximum receiver operating characteristic curve, and cost of testing, defined as the proportion of subjects needing two tests to diagnose disease. A method to incorporate the cost of testing into the definition of the optimal operating point is also presented. The performance of the testing strategies is examined with respect to the ratio of standard deviations and the correlation between test results under the bivariate normal assumptions. Under all parameter settings, the maximum receiver operating characteristic curve of the BE strategy never performed worse than the BN and BP strategies; the BE strategy also had the lowest cost. The use of body mass index and plasma glucose concentration to diagnose diabetes in Pima Indians was presented as a real-world application. The optimal operating points found by the BN and BE strategies produce lower false positive rate values than the BP strategy for these data.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21976377     DOI: 10.1002/sim.4358

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Improving risk prediction for pancreatic cancer in symptomatic patients: a Saudi Arabian study.

Authors:  Anwar E Ahmed; Faris S Alzahrani; Ahmed M Gharawi; Salman A Alammary; Fahad H Almijmaj; Fahad M Alhusayni; Donna K McClish; Hamdan Al-Jahdali; Ashwaq A Al Olayan; Abdul Rahman Jazieh
Journal:  Cancer Manag Res       Date:  2018-10-25       Impact factor: 3.989

2.  Factors associated with recovery delay in a sample of patients diagnosed by MERS-CoV rRT-PCR: A Saudi Arabian multicenter retrospective study.

Authors:  Anwar E Ahmed; Hamdan Al-Jahdali; Mody Alaqeel; Salma S Siddiq; Hanan A Alsaab; Ezzeldin A Sakr; Hamed A Alyahya; Munzir M Alandonisi; Alaa T Subedar; Yosra Z Ali; Hazza Al Otaibi; Nouf M Aloudah; Salim Baharoon; Sameera Al Johani; Mohammed G Alghamdi
Journal:  Influenza Other Respir Viruses       Date:  2018-04-25       Impact factor: 4.380

3.  Development of a risk-prediction model for Middle East respiratory syndrome coronavirus infection in dialysis patients.

Authors:  Anwar E Ahmed; Abeer N Alshukairi; Hamdan Al-Jahdali; Mody Alaqeel; Salma S Siddiq; Hanan A Alsaab; Ezzeldin A Sakr; Hamed A Alyahya; Munzir M Alandonisi; Alaa T Subedar; Nouf M Aloudah; Salim Baharoon; Majid A Alsalamah; Sameera Al Johani; Mohammed G Alghamdi
Journal:  Hemodial Int       Date:  2018-04-14       Impact factor: 1.812

4.  Early identification of pneumonia patients at increased risk of Middle East respiratory syndrome coronavirus infection in Saudi Arabia.

Authors:  Anwar E Ahmed; Hamdan Al-Jahdali; Abeer N Alshukairi; Mody Alaqeel; Salma S Siddiq; Hanan Alsaab; Ezzeldin A Sakr; Hamed A Alyahya; Munzir M Alandonisi; Alaa T Subedar; Nouf M Aloudah; Salim Baharoon; Majid A Alsalamah; Sameera Al Johani; Mohammed G Alghamdi
Journal:  Int J Infect Dis       Date:  2018-03-14       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.